New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
09:31 EDTNSRGY, VRXValeant completes filler, toxin asset sale to Galderma
Valeant Pharmaceuticals (VRX) announced it has completed the sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4B in cash, pursuant to the previously announced agreement with Nestle (NSRGY) which recently completed its acquisition of Galderma.
News For VRX;NSRGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:05 EDTVRXValeant outlook has improved, says RBC Capital
Subscribe for More Information
December 17, 2014
10:53 EDTVRXAckman says 'will take hard look' at Valeant shares after restrictions end
Subscribe for More Information
December 9, 2014
09:31 EDTVRXZoetis drops after report of Valeant abandoning growth by acquisitions strategy
Subscribe for More Information
06:39 EDTVRXValeant to abandon growth by acquisitions strategy, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use